Shobana Anpalakhan, Prerana Huddar, Roya Behrouzi, Alessio Signori, Judith Cave, Charles Comins, Alessio Cortellini, Alfredo Addeo, Carles Escriu, Hayley McKenzie, Gloria Barone, Lisa Murray, David J Pinato, Christian Ottensmeier, Sara Campos, Sethupathi Muthuramalingam, Samuel Chan, Fabio Gomes, Giuseppe L Banna
BACKGROUND: The Spinnaker study evaluated survival outcomes and prognostic factors in patients with advanced non-small-cell lung cancer receiving first-line chemoimmunotherapy in the real world. This sub-analysis assessed the immunotherapy-related adverse effects (irAEs) seen in this cohort, their impact on overall survival (OS) and progression-free survival (PFS), and related clinical factors. METHODS: The Spinnaker study was a retrospective multicentre observational cohort study of patients treated with first-line pembrolizumab plus platinum-based chemotherapy in six United Kingdom and one Swiss oncology centres...
2023: Frontiers in Oncology